d2644e613f

Novartis eyecare unit Alcon to set up new HQ in Geneva, Switzerland

pharmafile | September 11, 2018 | News story | Manufacturing and Production Alcon, Novartis, eye care, pharma 

Alcon, the eyecare unit of Novartis, is set to move to a new home next year, after its parent company revealed that the Swiss city of Geneva had been chosen as its new headquarters.

The location will be the second of two sites which will serve as the company’s global headquarters, alongside its regional office for Europe, Middle East and Africa which is already located in the city. The new site will host the firm’s senior corporate leadership, and promises “a modern office complex offering world-class services and amenities, including close proximity to the Geneva international airport”.    

The decision means it will relocate from its current longtime home in Texas following completion of the company’s proposed spin-off from Novartis next year, where it has dwelt since Alcon’s founding in 1945. While the company plans to employ around 700 at its new Swiss home, the US site will reportedly remain a major one.

“We are delighted to announce Geneva as the location of Alcon’s new global headquarters following the proposed spinoff from Novartis,” said David Endicott, Chief Executive Officer at Alcon. “For more than 40 years, Alcon has had a significant presence in Switzerland, which is known for its progressive business climate and innovation-friendly policies. Being headquartered in Geneva will help further increase Alcon’s global scale and reach to better serve our customers.”

Matt Fellows

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Novartis to acquire MorphoSys AG for €2.7bn

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …

Latest content